Catalyst Pharmaceuticals Inc (CPRX)

Operating return on assets (Operating ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	195,124	173,973	85,876	78,329	86,812	75,921	138,211	120,081	101,838	83,779	72,681	59,950	52,385	48,261	45,961	40,405	41,304	40,693	42,834	43,511
Total assets	US$ in thousands	851,411	772,010	706,360	646,676	471,907	413,211	443,896	407,227	375,630	333,114	267,309	246,972	237,788	223,248	209,130	197,216	192,354	174,860	131,412	117,880
Operating ROA		22.92%	22.54%	12.16%	12.11%	18.40%	18.37%	31.14%	29.49%	27.11%	25.15%	27.19%	24.27%	22.03%	21.62%	21.98%	20.49%	21.47%	23.27%	32.60%	36.91%

December 31, 2024 calculation

Operating ROA = Operating income (ttm) ÷ Total assets
= $195,124K ÷ $851,411K
= 22.92%

The operating return on assets (operating ROA) of Catalyst Pharmaceuticals Inc has exhibited fluctuations over the analyzed period. The company's operating ROA was relatively high at 36.91% as of March 31, 2020, showing strong operational efficiency in generating profit from its assets. Subsequently, the operating ROA decreased to 12.11% by March 31, 2024, indicating a decline in the company's ability to generate earnings from its assets efficiently.

During the period under review, Catalyst Pharmaceuticals Inc's operating ROA experienced both upward and downward trends, with notable fluctuations. The highest point was reached on June 30, 2023, at 31.14%, indicating improved operational performance and profitability from the assets. However, there was a substantial drop to 18.37% as of September 30, 2023, which could signify operational challenges or a less efficient asset utilization.

Overall, the analysis of Catalyst Pharmaceuticals Inc's operating ROA suggests variability in the company's ability to generate profits from its assets efficiently. Investors and stakeholders may need to closely monitor these fluctuations to assess the company's operational performance and financial health accurately.